BRPI9914151B8 - - Google Patents

Info

Publication number
BRPI9914151B8
BRPI9914151B8 BR9914151A BR9914151A BRPI9914151B8 BR PI9914151 B8 BRPI9914151 B8 BR PI9914151B8 BR 9914151 A BR9914151 A BR 9914151A BR 9914151 A BR9914151 A BR 9914151A BR PI9914151 B8 BRPI9914151 B8 BR PI9914151B8
Authority
BR
Brazil
Application number
BR9914151A
Other languages
Portuguese (pt)
Other versions
BRPI9914151B1 (pt
BR9914151A (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9914151(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9914151A publication Critical patent/BR9914151A/pt
Publication of BRPI9914151B1 publication Critical patent/BRPI9914151B1/pt
Publication of BRPI9914151B8 publication Critical patent/BRPI9914151B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9914151-5A 1998-09-30 1999-09-29 Antibiotic compositions for eye treatment and use of the same BRPI9914151B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10250498P 1998-09-30 1998-09-30
US10250698P 1998-09-30 1998-09-30
US60/102,506 1998-09-30
US60/102,504 1998-09-30
PCT/US1999/022622 WO2000018386A2 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Publications (3)

Publication Number Publication Date
BR9914151A BR9914151A (pt) 2001-06-26
BRPI9914151B1 BRPI9914151B1 (pt) 2017-10-03
BRPI9914151B8 true BRPI9914151B8 (US07714131-20100511-C00006.png) 2021-05-25

Family

ID=26799441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9914151-5A BRPI9914151B1 (pt) 1998-09-30 1999-09-29 Antibiotic compositions for eye treatment and use of the same

Country Status (18)

Country Link
EP (5) EP2269602B1 (US07714131-20100511-C00006.png)
JP (5) JP2002525317A (US07714131-20100511-C00006.png)
KR (1) KR101463243B1 (US07714131-20100511-C00006.png)
CN (2) CN100374114C (US07714131-20100511-C00006.png)
AR (2) AR020661A1 (US07714131-20100511-C00006.png)
AT (2) ATE501732T1 (US07714131-20100511-C00006.png)
AU (1) AU762827B2 (US07714131-20100511-C00006.png)
BR (1) BRPI9914151B1 (US07714131-20100511-C00006.png)
CA (3) CA2342211C (US07714131-20100511-C00006.png)
CY (3) CY1111404T1 (US07714131-20100511-C00006.png)
DE (2) DE69943287D1 (US07714131-20100511-C00006.png)
DK (5) DK2301541T3 (US07714131-20100511-C00006.png)
ES (4) ES2526521T3 (US07714131-20100511-C00006.png)
HK (4) HK1150756A1 (US07714131-20100511-C00006.png)
PT (5) PT2301541E (US07714131-20100511-C00006.png)
TR (2) TR200100883T2 (US07714131-20100511-C00006.png)
TW (1) TWI222361B (US07714131-20100511-C00006.png)
WO (1) WO2000018386A2 (US07714131-20100511-C00006.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
TR200200737T2 (tr) 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose
WO2002007704A2 (en) 2000-07-26 2002-01-31 Alcon Universal Ltd. Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
WO2002040028A1 (fr) * 2000-11-16 2002-05-23 Wakamoto Pharmaceutical Co., Ltd. Gouttes pour les yeux en gel antibacterien
AU2002226926A1 (en) * 2000-12-20 2002-07-01 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
AU2002228660A1 (en) 2000-12-20 2002-07-01 Alcon, Inc Use of amidoamines to treat or prevent acanthamoeba and fungal infections
MXPA04002576A (es) 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
JP2008512383A (ja) * 2004-09-03 2008-04-24 ピードモント ファーマシューティカルズ エルエルシー 中耳炎の経膜治療方法および予防方法
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
ZA200704775B (en) * 2004-12-10 2008-08-27 Alcon Inc Compositions for treatment of ear infections
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI495469B (zh) 2008-06-09 2015-08-11 Alcon Res Ltd 含有氟喹諾酮抗生素藥物之經改良藥學組成物
ES2694775T3 (es) * 2009-07-02 2018-12-27 Merlion Pharmaceuticals Pte., Ltd. Composiciones que comprenden finafloxacina y métodos de tratamiento de infecciones oftálmicas, óticas y nasales
PT2521547T (pt) * 2010-01-07 2017-11-17 Novartis Ag Métodos e composições para a aplicação de moxifloxacina no ouvido
BR112014012885A2 (pt) 2011-12-06 2017-06-13 Alcon Res Ltd composição de gel celulósica com estabilidade de viscosidade aperfeiçoada
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
CN108348516B (zh) * 2015-10-29 2021-02-12 特一华制药株式会社 外用剂
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
MX2022015836A (es) * 2020-06-10 2023-03-28 Ocular Science Inc Composiciones y metodos para el cuidado ocular posoperatorio.
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
TW209865B (US07714131-20100511-C00006.png) * 1992-01-10 1993-07-21 Bayer Ag
EP0639070B2 (en) 1992-05-06 2010-09-08 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd 5−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE214931T1 (de) * 1995-06-06 2002-04-15 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
PL192273B1 (pl) * 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
EP1115371B1 (en) 1998-09-23 2005-03-16 Unilever N.V. Oral care compositions
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법

Also Published As

Publication number Publication date
HK1059572A1 (en) 2004-07-09
CY1111404T1 (el) 2015-08-05
JP2002525317A (ja) 2002-08-13
CY1115759T1 (el) 2017-01-25
EP1117401A2 (en) 2001-07-25
AU762827B2 (en) 2003-07-03
PT2796138T (pt) 2016-09-22
HK1038691B (zh) 2004-04-23
EP2269602A1 (en) 2011-01-05
AR081393A2 (es) 2012-08-29
PT2269602E (pt) 2014-12-29
EP2269602B1 (en) 2014-11-19
KR101463243B1 (ko) 2014-12-17
CA2342211A1 (en) 2000-04-06
CN1650863A (zh) 2005-08-10
DK2269602T3 (en) 2014-12-15
PT2301541E (pt) 2014-10-29
HK1150756A1 (en) 2012-01-13
TR200704370T2 (tr) 2007-11-21
WO2000018386A2 (en) 2000-04-06
EP2301541B1 (en) 2014-08-20
ATE254458T1 (de) 2003-12-15
TWI222361B (en) 2004-10-21
WO2000018386A3 (en) 2000-06-08
DE69943287D1 (de) 2011-04-28
AU1310100A (en) 2000-04-17
JP2012067141A (ja) 2012-04-05
HK1038691A1 (en) 2002-03-28
CA2774207A1 (en) 2000-04-06
BRPI9914151B1 (pt) 2017-10-03
KR20010075138A (ko) 2001-08-09
DE69912972D1 (de) 2003-12-24
DK2301541T3 (da) 2014-09-01
EP1384478B1 (en) 2011-03-16
ES2526521T3 (es) 2015-01-13
PT1117401E (pt) 2004-03-31
EP1117401B1 (en) 2003-11-19
ATE501732T1 (de) 2011-04-15
AR020661A1 (es) 2002-05-22
CN1184968C (zh) 2005-01-19
DE69912972T2 (de) 2004-04-22
PT1384478E (pt) 2011-05-12
CA2659064A1 (en) 2000-04-06
JP2013018799A (ja) 2013-01-31
EP1384478A1 (en) 2004-01-28
ES2519190T3 (es) 2014-11-06
ES2602956T3 (es) 2017-02-23
EP2796138A1 (en) 2014-10-29
DK1117401T3 (da) 2004-02-23
CN1320035A (zh) 2001-10-31
JP2014144982A (ja) 2014-08-14
DK2796138T3 (en) 2016-12-05
BR9914151A (pt) 2001-06-26
CY1115916T1 (el) 2017-01-25
EP2301541A1 (en) 2011-03-30
HK1150769A1 (en) 2012-01-13
TR200100883T2 (tr) 2001-10-22
EP2796138B1 (en) 2016-08-17
CA2342211C (en) 2009-05-26
JP2009007375A (ja) 2009-01-15
JP5563041B2 (ja) 2014-07-30
CN100374114C (zh) 2008-03-12
DK1384478T3 (da) 2011-05-23
ES2207307T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
JP2001524345A5 (US07714131-20100511-C00006.png)
BE2009C051I2 (US07714131-20100511-C00006.png)
JP2001525499A5 (US07714131-20100511-C00006.png)
JP2002508576A5 (US07714131-20100511-C00006.png)
JP2002508212A5 (US07714131-20100511-C00006.png)
JP3060285U7 (US07714131-20100511-C00006.png)
JP2000017102A6 (US07714131-20100511-C00006.png)
JP2612545C (US07714131-20100511-C00006.png)
JP2546136C (US07714131-20100511-C00006.png)
JP2528088Z (US07714131-20100511-C00006.png)
JP2525513C (US07714131-20100511-C00006.png)
JP2525242Z (US07714131-20100511-C00006.png)
JP2524028C (US07714131-20100511-C00006.png)
JP2535279C (US07714131-20100511-C00006.png)
JP2528441C (US07714131-20100511-C00006.png)
JP2584743C (US07714131-20100511-C00006.png)
JP2589695C (US07714131-20100511-C00006.png)
JP2615152C (US07714131-20100511-C00006.png)
IN190688B (US07714131-20100511-C00006.png)
IN187817B (US07714131-20100511-C00006.png)
ECSDI980474S (US07714131-20100511-C00006.png)
JP2631561C (US07714131-20100511-C00006.png)
CN3083603S (US07714131-20100511-C00006.png)
CN3080931S (US07714131-20100511-C00006.png)
CN3078571S (US07714131-20100511-C00006.png)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/4709, A61K 31/573, A61P 31/04

Ipc: A61K 31/4709 (2007.10), A61K 31/573 (2007.10), A61

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI 9.279 DE 14/05/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)
B25B Requested transfer of rights rejected

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870200007757 DE 16/01/2020,EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2548 DE 05/11/2019.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.004729/2020-88 ORIGEM: 2A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1011651-31.2020.4.01.3400 NULIDADE DE ATO ADMINISTRATIVO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: NOVARTIS PHARMA AG REU(S): EMS S.A. E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL"

B12F Other appeals [chapter 12.6 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/09/2019

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.